Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$6.56 - $10.95 $24.3 Million - $40.6 Million
3,703,795 Added 110.2%
7,064,736 $48.4 Million
Q1 2023

May 15, 2023

BUY
$7.07 - $17.95 $596,693 - $1.51 Million
84,398 Added 2.58%
3,360,941 $27.2 Million
Q4 2022

Feb 14, 2023

SELL
$14.33 - $18.37 $10 Million - $12.9 Million
-700,000 Reduced 17.6%
3,276,543 $51.6 Million
Q1 2022

May 16, 2022

BUY
$9.74 - $17.92 $22.2 Million - $40.9 Million
2,280,639 Added 134.48%
3,976,543 $68.6 Million
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.49 $3.96 Million - $5.97 Million
322,860 Added 23.51%
1,695,904 $24.7 Million
Q3 2021

Nov 15, 2021

BUY
$13.38 - $18.8 $4.99 Million - $7.01 Million
373,044 Added 37.3%
1,373,044 $24.7 Million
Q2 2021

Aug 16, 2021

BUY
$17.08 - $29.6 $17.1 Million - $29.6 Million
1,000,000 New
1,000,000 $17.6 Million

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $255M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Bvf Inc Portfolio

Follow Bvf Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.